1-Next week marks the beginning of numerous milestone announcements including restart of spine trials.
2-BTX in R&D/building phase for last seven years and finally about to announce multiple clinical trials
3-Two 'low hanging fruit' products: lung cancer diagnostic product PanC-DX, LifeMap medical App.
4-BTX currently pulling out of a 5 yr low
5-Currenly holds most stem cell patents for one single company worldwide
6-Balanced approach, with growing research products and many regen therapeutics on the way
7-A+ biz plan with seven subsidiaries, no debt, world renowned CEO's & scientific leaders
8-Building best in class corporate/institutional partners including, CIRM, TEVA, Weill Cornell, Wistar Institute, Mt Sini, Spain Stem Cell Center, USC, Millipore and more to be announced in coming weeks.
9-Owns worlds most popular online genetic database company LifeMaps which is currently developing next-gen personalized medicine app(partner: with Mt Sini Memorial genetic dept.).
10-Recently IPO'ed first subsidiary Astrias, next year likely to have more IPO's
Hope some have found this info useful !
“We are very pleased with the progress that Cell Cure’s team has made in preparing for the company’s FDA submission,” said Charles S. Irving PhD, Cell Cure’s CEO. “We look forward to initiating the clinical trial that will utilize for the first time high quality, xeno-free grade RPE cells for the treatment of geographic atrophy, the severe stage of dry-AMD.”
Some misinformation posted on this board by stock shorters.....let me post some facts here:
In 2010 BTX announced the start of their cancer diagnostics program...they INSTANTLY shot to an intra-day high of $10. Fast forward four yeas....BTX partners are growing, UCLA, Wistar Institute, Weill Cornell and now Abcodia Ltd.
Our first product to be released will most likely be PanC-DX for lung cancer, currently finishing up blood sample data with Weill Cornell and will be released in late 2014 in the EU.
Biotime is totally under the radar like most stem cell stocks. Later this year our cancer diagnostic products will start finishing trials, partner and prepare to hit the market. By early next year your average investor will take notice and talking heads like MadMoneys Cramer will start taking Lightning Round calls about us.
Just listened to today's presentation by Dr. west and here are a few quotes and tidbits I came away with:
"Several milestones kicking in durning second half of this year as well as early next year."
-Pre-clinical programs to start for MS and stroke
-AMD (animal free) trials-TEVA partnership-start this year
-Renevia, entering pivotal trial, 15 year patent life,cosmetic/HIV
-Premivia FDA excepted, start tendon repair program
-Oncocyte: late this year reporting on clinical trials for lung bladder and breast cancer diagnostics. "Breast cancer alone a 2 BIL market and replacement for mammography modality." "Bladder PanC-DX tests patients urine replacing biopsy, and lung PanC replacing low dose catscan for high risk patients."
At this point BTX. World first cancer diagnostic product to be released in EU market by years end. Our nano breast cancer blood test is so sensitive it will replace the need for mammograms, and our bladder cancer PanC-DX is a urine test. Lung cancer being developed along with NYC Weil Cornell.
And if that's not enough for you we also have LifeMap Medical research app 1.0 also out by years end.
Icon, a few years ago hit an intra-day high of $10 when they announced the start of their cancer diagnostics program. It's been three years and our partners Wistar Institute and Weill Cornell are prepping release. First release to market will be in the EU before years end. I would expect BTX to have a major pop at that time.
Best of luck!
Correction: BTX didn't 'steal' Nat Ricciardi, he spent nearly 40 years with Pfizer before retiring. Great pick up for AST's board no doubt.
LifeMap already has the largest researcher based genetic/stemcell database, an upgrade early next year should keep them at the forefront.
Stem Cell News today:
In a boon to stem cell research and regenerative medicine, scientists at Boston Children's Hospital, the Wyss Institute for Biologically Inspired Engineering at Harvard University and Boston University have created a computer algorithm called CellNet as a "roadmap" for cell and tissue engineering, to ensure that cells engineered in the lab have the same favorable properties as cells in our own bodies. CellNet and its application to stem cell engineering are described in two back-to-back papers in the August 14 issue of the journal Cell.
Scientists around the world are engaged in culturing pluripotent stem cells (capable of forming all the body's tissues) and transforming them into specialized cell types for use in research and regenerative medicine. Available as an Internet resource for any scientist to use, CellNet provides a much needed "quality assurance" measure for this work.
Little by little coming out from under the radar. Cancer diagnostic products out early next year! Buy now before Wall St and Cramer start!
PanCDX products will start to come to market at that time. Current status quo breast cancer diagnostics are archaic, Biotime will help change this.
And at $2.56. Buy of a life time.
BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OncoCyte Corporation today announced that OncoCyte has expanded the clinical development of its urine-based bladder cancer diagnostic test by initiating a multi-site clinical trial. The trial, which will involve up to 1,200 patient samples obtained from at least four large urology clinics located throughout the United States, has received Institutional Review Board (IRB) approval at multiple sites and should begin enrolling patients within the next week. OncoCyte’s initial clinical study of its bladder cancer diagnostic test began in January and involves pathology specimens being collected at a leading medical institution with an international reputation for excellence and discovery. The multi-site clinical trial, which has been initiated in part due to positive interim data from the ongoing study in pathology specimens, is designed to expand the potential use of the PanC-Dx™ bladder cancer test beyond pathology laboratories and into urologic practices at the point of cystoscopy. Cystoscopy along with urine cytopathology, are the standard methods utilized for bladder cancer screening and diagnosis. The multi-site clinical trial should be completed within 12 months.